Genmab A/S · OMXCOP:GMAB
Genmab A/S — Q1 2010 Earnings Presentation
7 slides from Genmab A/S's earnings presentation, Mar 31, 2010
Slide 1: Financial Summary
Financial Summary For 3 months ended March 31, 2010
Slide 2: Forward Looking Statement
Forward Looking Statement This presentation contains forward looking statements. The words “believe”, “expect”, “anticipate”, “intend” and “plan” and similar expressions identify forward looking statements. All statements other than statements of historical facts included in this presentation, inclu
Slide 3: Financial Summary – Key Data
Q1 Interim Report 2010 Financial Summary – Key Data 3 Months ended March 31, 2010 2010 2009 2010 2009 DKK millions USD millions * Revenue 107 250 19 45 Net Loss (130) (199) (24) (36) R&D employees 239 482 All other employees 37 50 Employees at end of period 276 532 DKK millions USD millions * Cash a
Slide 4: Financial Summary – Income Statement
Q1 Interim Report 2010 Financial Summary – Income Statement 3 Months ended March 31, 2010 2010 2009 2010 2009 DKK millions USD millions * Revenue 107 250 19 45 R&D Costs (221) (247) (40) (45) G&A Expenses (33) (40) (6) (7) Operating Expenses (254) (287) (46) (52) Operating Loss (147) (37) (27) (7) N
Slide 5: Highlights
Q1 Interim Report 2010 Highlights Ofatumumab European conditional marketing authorization for refractory CLL received Milestone for DKK 87 million triggered by European approval First quarter Arzerra sales reported generating DKK 8 million of royalty 20 studies ongoing, including 9 Phase III's New P
Slide 6: Guidance 2010
Guidance 2010 Note Arzerra Royalties are not Guidance 2010 included in the guidance DKK Millions USD Millions * Revenue 350 - 450 63 - 81 Operating Expenses (950) - (1,050) (172) - (190) Operating Loss from Continuing Ops. (550) - (650) (100) - (118) Discontinued Operations (55) (10) Facility Sale 8
Slide 7: Slide 7